Breaking Finance News

A report released today by Chardan Capital about Arbutus Biopharma (NASDAQ:ABUS) bumps the target price to $4.00

Yesterday Arbutus Biopharma (NASDAQ:ABUS) traded -1.85% lower at $2.65. Arbutus Biopharma’s 50-day moving average is $2.95 and its 200-day moving average is $3.61. The last closing price is down -26.57% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the date range. Volume of trade was down over the average, with 0 shares of ABUS changing hands under the typical 148,736

Chardan Capital increased the stock price target of Arbutus Biopharma (NASDAQ:ABUS) to $4.00 stating a potential upside of 0.51%.

On 12/21/2015, RBC Capital Markets released a statement about Arbutus Biopharma (NASDAQ:ABUS) bumped down the target price from $20.00 to $12.00. At the time, this indicated a possible upside of 1.57%.

See Chart Below

Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma has 52 week low of $2.45 and a one year high of $5.70 and has a total market value of $0.

A total of 5 equity analysts have released a ratings update on ABUS. 2 brokers rating the stock a strong buy, 3 firms rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally zero equity analysts rating the company a sell with a one year target of $13.80.

General Company Details For Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.